Hospital
Christus Hopkins Health Alliance
Christus Hopkins Health Alliance was paid $4.96M by Medicaid between Jul 2020 and Nov 2024, across 83 billing codes. Its largest line is 99284, emergency room visit (serious) — 37% of everything it billed.
33Billing provider infoCHRISTUS HOPKINS HEALTH ALLIANCE
SULPHUR SPRINGS, TX 75482
SULPHUR SPRINGS, TX 75482
33aNPI1033568621assigned 06/06/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.96M
24GClaims71,117
24DCodes billed83
24AFirst – last monthJul 2020 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#36 of 109
Median peer was paid$1.15M
This provider vs. median4.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,671 | $74K | |
| 2021 | 18,784 | $756K | |
| 2022 | 20,687 | $1.53M | |
| 2023 | 19,261 | $1.82M | |
| 2024incomplete | 9,714 | $776K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 37% | 3,488 | 3,169 | $1.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 7,175 | 7,014 | $1.56M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 572 | 534 | $453K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.0% | 3,805 | 3,466 | $200K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 1,200 | 1,185 | $149K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.5% | 3,173 | 2,820 | $122K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.2% | 936 | 924 | $107K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,193 | 1,097 | $48K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,550 | 1,399 | $47K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,710 | 6,737 | $46K |
| 80053 | Comprehensive metabolic panel | <1% | 5,252 | 4,756 | $46K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 133 | 128 | $34K |
71 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 255 | $28K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 273 | $24K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 265 | $22K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,023 | $21K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 307 | $21K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 305 | $17K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 305 | $17K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 436 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,275 | $12K |
| 83880 | <1% | 839 | $11K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 95 | $10K |
| 87070 | <1% | 690 | $9K | |
| 73110 | <1% | 60 | $9K | |
| 81003 | <1% | 3,142 | $9K | |
| 81001 | <1% | 3,172 | $9K | |
| 87428 | <1% | 111 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,534 | $7K |
| 80061 | Lipid panel | <1% | 1,481 | $7K |
| 84484 | <1% | 1,480 | $7K | |
| 20610 | <1% | 335 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,429 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 209 | $6K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 196 | $5K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 60 | $5K |
| 83690 | <1% | 610 | $2K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 630 | $2K |
| 81025 | <1% | 147 | $2K | |
| 74018 | <1% | 15 | $2K | |
| 87807 | <1% | 81 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 630 | $2K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 76 | $1K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 61 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 112 | $1K |
| 85610 | <1% | 527 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $994.14 |
| Q3014 | Telehealth originating site facility fee | <1% | 30 | $903.02 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 700 | $827.96 |
| 83605 | <1% | 215 | $747.91 | |
| 87186 | <1% | 176 | $712.74 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 41 | $695.90 |
| 81002 | <1% | 258 | $642.57 | |
| 84439 | <1% | 102 | $548.74 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 34 | $530.55 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 28 | $449.64 |
| 88142 | <1% | 12 | $439.60 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14 | $425.58 |
| 87081 | <1% | 29 | $385.96 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $287.12 |
| 0240U | <1% | 645 | $285.26 | |
| 83735 | <1% | 74 | $172.54 | |
| 84703 | <1% | 15 | $155.57 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 79 | $129.53 |
| 82570 | <1% | 67 | $128.34 | |
| 82043 | <1% | 38 | $104.61 | |
| 85730 | <1% | 58 | $103.16 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 13 | $57.05 |
| 86850 | <1% | 12 | $47.60 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 259 | $45.50 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 114 | $29.70 |
| 86901 | <1% | 13 | $14.78 | |
| 86900 | <1% | 13 | $14.78 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,867 | $11.96 |
| 90686 | <1% | 43 | $11.86 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 429 | $3.51 |
| 82962 | 0% | 456 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 133 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 13 | $0.00 |
| 36416 | 0% | 12 | $0.00 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | 0% | 658 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 54 | $0.00 |
| 90662 | 0% | 34 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCANDREW, MICHAEL (CEO)
Parent organizationCHRISTUS HEALTH